OR WAIT null SECS
© 2024 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
ePT--the Electronic Newsletter of Pharmaceutical Technology
Dallas, TX (Nov. 7)-The US Food and Drug Administration has posted a Warning Letter from its Dallas District office to Matheson Tri-Gas, Inc.
Dallas, TX (Nov. 7)-The US Food and Drug Administration has posted a Warning Letter (http://www.fda.gov/foi/warning_letters/g6096d.htm) from its Dallas District office to Matheson Tri-Gas, Inc. (Parsippany, NJ, www.mathesontrigas.com). The three-page letter, dated Sept. 12, detailed findings of inspections, in March and April of this year, of a Matheson medical gas facility in Houston, and reviewed the company's April 19 response to the inspectors' Form 483 observations.
The Warning includes three citations, noting shortcomings in: